The panel discussion centered on the optimization of leukemia treatment, particularly focusing on the combination of venetoclax with various therapies. Preclinical data and pathophysiology were explored, highlighting the potential of inhibiting JAK2 mutations with venetoclax.
REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS
AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/
AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/
MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/
Concerns were raised about CNS relapse and CD19-negative relapses, emphasizing the need for continued IT chemotherapy. The balance between systemic chemotherapy reduction and comprehensive coverage with antigen-directed therapies was a key consideration.